日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer: randomized phase II study

在BRCA1/2局部复发/转移性乳腺癌患者中,维利帕尼联合替莫唑胺或卡铂/紫杉醇与安慰剂联合卡铂/紫杉醇的疗效比较:一项随机II期研究

Han, H S; Diéras, V; Robson, M; Palácová, M; Marcom, P K; Jager, A; Bondarenko, I; Citrin, D; Campone, M; Telli, M L; Domchek, S M; Friedlander, M; Kaufman, B; Garber, J E; Shparyk, Y; Chmielowska, E; Jakobsen, E H; Kaklamani, V; Gradishar, W; Ratajczak, C K; Nickner, C; Qin, Q; Qian, J; Shepherd, S P; Isakoff, S J; Puhalla, S

A phase 1 dose-escalation study of veliparib with bimonthly FOLFIRI in patients with advanced solid tumours

一项针对晚期实体瘤患者的维利帕尼联合双月一次FOLFIRI方案的1期剂量递增研究

Berlin, Jordan; Ramanathan, Ramesh K; Strickler, John H; Subramaniam, Deepa S; Marshall, John; Kang, Yoon-Koo; Hetman, Robert; Dudley, Matthew W; Zeng, Jiewei; Nickner, Caroline; Xiong, Hao; Komarnitsky, Philip; Shepherd, Stacie Peacock; Hurwitz, Herbert; Lenz, Heinz-Josef